Get started

Phase3

$SAGE: strong base, upcoming catalysts$SAGE is an interesting stock here, has pending catalysts for mid 2023, which fit the expectations from the Time@Mode technical pattern at hand here. Consider the volatility of these biotech names when entering, stock could move huge after data comes out (up or down) but odds are good that it breaks to the upside given the technical pattern suggesting the smart money has been accumulating stock. Upcoming catalysts: SAGE-217 - (SHORELINE) Major Depressive Disorder (MDD) Phase 3 additional data due in mid-2023. Zuranolone (SAGE-217) Major depressive disorder (MDD) and Postpartum Depression PDUFA priority review date of August 5, 2023. Best of luck! Cheers, Ivan Labrie.
NASDAQ:SAGELong
by IvanLabrie
1
EVFM 53X Upside potential according to Morgan Stanley !EVFM Evofem Biosciences has a big upcoming catalyst: Its Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women is on track to report top-line data from this landmark trial in mid-October, so we are one week away from results! Positive study outcomes would enable potential U.S. approval for prevention of these sexually transmitted infections in 2023. Evofem`s Phexxi whas already approved in Nigeria, the most populous country in Africa and the seventh largest country in the world, 3 days ago. On 4/12/2022 Jeffrey Hung from Morgan Stanley Boosted the Price Target for EVFM to Underweight, from $7.95 to $8.55. On 8/15/2022 HC Wainwright Boosted the Price Target to $4.00, giving a Buy Rating. Now the stock is trading at all time low, $0.16, while 4 months ago it was trading 10X higher. In my opinion this is a premium call and a great buy opportunity ahead of a Big upcoming catalyst for EVFM Evofem Biosciences. Looking forward to read your opinion about it.
OTC:EVFMLong
by TopgOptions
1
Bluebird Bio Inc 🧙bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates. Here you can see pipeline: Betibeglogene autotemcel (beti-cel) (LentiGlobin) - HGB-212 Northstar-3 Phase 3 updated at EHA June 11, 2021. 89% (32/36) of evaluable patients achieved transfusion independence (TI) and remain transfusion free (HGB-207, HGB-212) Betibeglogene autotemcel (beti-cel) (LentiGlobin) - HGB-207 Northstar-2 Phase 3 updated at EHA June 11, 2021. 89% (32/36) of evaluable patients achieved transfusion independence (TI) and remain transfusion free (HGB-207, HGB-212) Lenti-D (Elivaldogene Autotemcel / Eli-Cel) - ALD-102 Phase 2/3 updated data presented March 15, 2021. 90% of evaluable patients (27/30) alive and free of major functional disabilities at two years follow-up. Betibeglogene autotemcel (beti-cel) (LentiGlobin) BLA filing to be completed Betibeglogene autotemcel (beti-cel) (LentiGlobin) - HGB-206 Phase 1/2 trial temporarily suspended due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) - February 16, 2021. Clinical hold lifted June 7, 2021. Data to be presented by end of 2021. Lenti-D (Elivaldogene Autotemcel / Eli-Cel) - ALD-104 Phase 3 safety data to be presented at EBMT 2020. Noted two adverse events (out of 13 patients) of pancytopenia were considered possibly related to Lenti-D. Phase 3 trial placed on clinical hold - noted August 9, 2021. BLA filing due 2021 subject to resolution of the clinical hold. ABECMA (idecabtagene vicleucel) Phase 1 data presented at ASH 2020. bb21217 (CRB-402) Phase 1 data due by end of 2021. MGTA-145 and plerixafor Phase 2 trial to be initiated 4Q 2021. Betibeglogene autotemcel (beti-cel) (LentiGlobin) - (HGB-210) Phase 3 trial temporarily suspended due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) - February 16, 2021. Clinical hold lifted June 7, 2021.
NASDAQ:BLUELong
by yura_trades
MGEN Done Going Down Or Just A Pit Stop?MGEN has been getting hammered lately. Not one single green close in the last few weeks. Friday was the first, somewhat green close and that ain't saying much. But trading action was interesting. "riday’s action was something much different than what the penny stock had seen during the 2 weeks prior. It was the first trading day that MGEN shares didn’t close red. If you look at the chart, since October 9th, the penny stock saw a red close every day...Furthermore, trading action continued to push shares higher during after-hours on Friday." Original Quote Source: 5 Penny Stocks On Robinhood To Buy Under $2; Are They Too Risky?
M
by PennyStocks101